INTRODUCTION
============

Atherosclerosis, the leading cause of cardiovascular disease, is formerly considered a chronic inflammatory disease. However, increasing evidence suggests that oxidative stress-induced DNA damage induces the apoptosis of VSMCs during the pathogenesis of atherosclerosis [@B001], [@B002]. For example, the level of 8-oxoG, a DNA adduct from oxidative damage, is significantly higher in VSMCs of the aorta wall [@B003], [@B004]. However, in response to DNA damage, cells usually activate DNA damage repair systems to repair DNA lesions. Thus, it is unclear why VSMCs are sensitive to oxidative damage.

Oxidative DNA damage is usually induced by reactive oxygen species (ROS) primarily generated from normal intracellular metabolism in mitochondria and peroxisomes. A number of external hazards such as ionizing radiation, chemicals and UVA solar light can also trigger ROS production [@B005], [@B006]. These active free radicals attack double-stranded DNA, inducing various types of DNA lesions, including DNA single-stand breaks (SSBs) and double-strand breaks (DSBs), which may lead to genomic instability [@B007], [@B008]. To cope with these threats, cells have evolved DNA damage response systems to detect and repair DNA lesions. As one of the earliest alarm systems and regulators in DNA damage response, poly(ADP-ribose) (PAR) participates in the repair of numerous types of DNA damage including SSBs and DSBs [@B009], [@B010]. Thus, the cellular metabolism of PAR is critical for DNA damage response and genomic stability. The reaction of poly(ADP-ribosyl)ation (PARylation) is catalyzed by a group of PAR polymerases (PARPs). Using NAD^+^ as the substrate, PARPs covalently adds ADP-ribose to the side chains of arginine, aspartic acid, and glutamic acid residues in target proteins. After catalyzing the first ADP-ribose onto the proteins, other ADP-riboses can be covalently linked and the continuous reactions produce both linear and branched polymers known as PAR [@B011], [@B012]. The structure of PAR has been well characterized: the ADP-ribose unit in the polymer is linked by glycosidic ribose-ribose 1'-2' bonds. The chain length is heterogeneous and can reach around 200 units with 20-50 units in each branch [@B013]. PARylation is regulated not only by PARPs but also by PARG, the major enzyme for hydrolyzing PAR. In response to DNA damage, PARG is recruited to DNA lesions and digest PAR within a few minutes.

Although PARylation has been examined both in vivo and in vitro, the metabolism of PAR in VSMCs remains elusive. In this study, we examined PAR metabolism following oxidative DNA damage in mouse aortic VSMCs (MOVAS), and used mouse embryonic fibroblasts (MEFs) as the control cell line. Similar to MOVAS, MEFs can be used to study DNA damage [@B014], [@B015] and originate from mesenchymal stem cells with the ability to differentiate into myocytes [@B016], [@B017]. With mass spectrometry, we quantitatively measured the level of PAR in MOVAS, and found that that it was relatively low. Our study also suggests that the PARG level in MOVAS is relatively high, which suppresses PARylation following oxidative damage, and thus affect DNA damage repair. Suppression of PARG by the PARG inhibitor facilitates PARylation and DNA damage repair in MOVAS. Thus, PARG inhibitor treatment could be a potential therapeutic approach for arteriosclerosis.

RESULTS AND DISCUSSION
======================

H~2~O~2~ induces DNA damage in MOVAS
------------------------------------

ROS is one of the most common by-products during metabolism and induces SSBs [@B018]. Under physiological conditions, ROS-induced SSBs can be repaired via the base excision repair pathway [@B019]. However, when two SSBs happen in close proximity, or when the DNA-replication apparatus encounters a SSB, DSBs, the more deleterious genomic lesion, are formed by overwhelming ROS [@B020], [@B021]. Excessive ROS imposes an oxidative stress condition on vascular cells especially VSMCs, triggering the apoptosis of VSMCs and arteriosclerosis [@B022], [@B023]. It is well known that ROS can be generated by externally adding H~2~O~2~ [@B024]. Thus, to study the oxidative DNA damage in MOVAS, we treated MOVAS with H~2~O~2~, and employed alkaline comet assays [@B025] to detect SSBs and DSBs in the cells. Damaged genomic DNA fragments migrated from nuclei during electrophoresis [Fig. 1](#F001){ref-type="fig"}A). Shorter DNA fragments move faster in electrophoresis, therefore, by measuring the migrated length of DNA fragments, we can quantitatively examine the repair of oxidative damage. To our surprise, we found that the repair in MOVAS was much slower than that in MEFs since much shorter DNA fragments were found in MOVAS especially at 60 minutes (MOVAS: 7.18 ± 0.99, MEFs: 2.68 ± 0.44, P = 0.000) and 120 minutes (MOVAS: 2.87 ± 0.24, MEFs: 0.70 ± 0.16, P = 0.000) following H~2~O~2~ treatment ([Fig. 1](#F001){ref-type="fig"}A, B).

![H~2~O~2~-induced DSBs activate DNA damage repair in MOVAS. (A) Representative images of alkaline comet assays at 20, 60, and 120 min following H~2~O~2~ treatment. Comet tails were found in H~2~O~2~ treated cells. (B) Quantification of DNA damage by tail moment of comet assay treated with or without H~2~O~2~. Tail moments were measured from three independent experiments with at least 30 cells at single time points per sample. (C) Cells were treated with various concentrations of H~2~O~2~, and visualized by immunostaining with anti-*γ*H2AX (red) following 1 h H~2~O~2~ treatment. Nuclei were stained with Hoechst 33258 (blue). (D) The number of *γ*H2AX foci in cells was counted (n = 15). The error bars represent the standard deviation, \*P ＜ 0.05.](BMB-48-354-g001){#F001}

The H~2~O~2~-induced DSBs in MOVAS and MEFs were examined by staining the cells with anti-*γ*H2AX antibody. We observed *γ*H2AX nuclear foci in MOVAS, suggesting that DSBs occurred in MOVAS following oxidative damage (the number of foci were 2.00 ± 1.75, 8.86 ± 2.21, 25.03 ± 7.93, 36.13 ± 7.06 per cell from the control group to each H~2~O~2~ group). Meanwhile, we found little *γ*H2AX foci in MEFs damage (the number of foci were 2.20 ± 2.10, 3.20 ± 2.05, 3.30 ± 3.06, 2.80 ± 2.77 per cell from the control group to each H~2~O~2~ group) ([Fig. 1](#F001){ref-type="fig"}C, D). Thus, these results suggest that oxidative damage-induced DSBs were not repaired in a timely manner in MOVAS unlike in MEFs, which may partly explain the molecular mechanism of VSMC death and arteriosclerosis.

PARylation is suppressed in MOVAS in response to oxidative DNA damage
---------------------------------------------------------------------

Next, we asked why MOVAS failed to repair all the oxidative lesions. We examined PARylation, because it is an immediate and dramatic posttranslational modification in response to DNA damage. PAR is a polymer of repeating ADP-ribose units with varying length and branches. Thus, quantitatively measuring PARylation is limited by the heterogeneous format of PAR. To overcome the limitation, we measured the amount of single ADP-ribose using mass spectrometry. We cut phosphate diester bonds within each ADP-ribose and removed the phosphate group by phosphotases to obtain a ribosyladenosine unit from PAR ([Fig. 2](#F002){ref-type="fig"}A). Thus, we were able to accurately measure the amount of ribosyladenosine units from PAR with a molecular weight of 400.146 by Q-TOF mass spectrometry. As seen in [Fig. 2](#F002){ref-type="fig"}B, mass spectrometry peaks from both MOVAS and MEFs showed identical molecular weights of 400.146, corresponding to ribosyladenosine. To compare the relative abundance of ribosyladenosine from MOVAS and MEFs, we used the peak height of ribosyladenosine. We found that H~2~O~2~ induced a higher ribosyladenosine peak value in MEFs than in MOVAS \[before and after H~2~O~2~ treatment ratio of ribosyladenosine peak: MOVAS: 1.61 ± 0.03, MEFs: 3.31 ± 0.05 ([Fig. 2](#F002){ref-type="fig"}B, C)\]. This result suggests that the amount of PAR generated in MEFs in response to oxidative DNA damage is greater than in MOVAS. To validate the results, we introduced two other cell lines, mouse aortic endothelial cells (MECs) and skeletal muscle cells (MSCs), and used dot blot assays to determine the amount of PAR in the cells. We found that the amount of PAR in MOVAS was much lower than in the other three cell lines after H~2~O~2~ treatment ([Fig. 2](#F002){ref-type="fig"}D). Meanwhile, we investigated PAR synthesis in the wire-injured mice model, which is reported to induce oxidative damage [@B026], [@B027]. The PAR-positive percentage in MECs was consistently higher than in MOVAS after wire injury ([Fig. 2](#F002){ref-type="fig"}E, F). Thus, a correlation between PAR synthesis and DNA damage repair in VSMCs was observed in both cell and animal experiments, further suggesting that PARylation plays an important role for oxidative DNA damage repair in VSMCs.

![PAR synthesis is suppressed in MOVAS. (A) Structure of PAR. In response to oxidant DNA damage, PARP-1 hydrolyzes NAD^+^, releases nicotinamide and one proton (H^+^), and transfers the ADP-ribose moiety (blue) to protein acceptors. Subsequent digestion of PAR with phosphodiesterase (red scissors) and phosphotase (purple scissors) releases ribosyladenosine (green). (B) Ribosyladenosine levels in MOVAS and MEFs were measured by Q-TOF mass spectrometry, and arbitrary units are shown in the histogram (C), the error bars represent the standard deviation, \*P＜0.05. (D) Following 20 min H~2~O~2~ treatment, PAR was purified from MOVAS, MEFs, MECs and MSCs, then examined by dot blot using anti-PAR antibody. β-actin was examined by western blot and used as the loading control. (E) Immunofluorescence staining of PAR in artery tissue (Scale bar = 100 ㎛). (F) The number of PAR positive cells are shown in the histogram. Error bars represent the standard deviation (n = 3), \*P＜0.05.](BMB-48-354-g002){#F002}

High expression of PARG decreases PARylation in MOVAS
-----------------------------------------------------

We next examined why the level of PAR in MOVAS was significantly lower than in the other cells. Since DNA damage-induced PAR is mainly synthesized by PARP-1, the founding member in PARPs family [@B013], we first examined the expression of PARP-1 in MOVAS and MEFs by immunofluorescence staining. We co-stained PAR and PARP-1 in the nuclei of both MOVAS and MEFs. As shown in [Fig. 3](#F003){ref-type="fig"}A, although the level of PAR was significantly higher in MEFs, the expression level of PARP-1 in MOVAS and MEFs did not show significant differences. To further examine the level of PARP-1, we analyzed PARP-1 in the above four cell lines by western blot ([Fig. 3](#F003){ref-type="fig"}B). Again, we did not observe significant differences in PARP-1's expression in the control and H~2~O~2~ treated cells. PARP-1 is the most important enzyme involved in oxidative DNA repair [@B028], which normally occurs in the cell nucleus. When DNA damage occurs, PARP-1 is activated and recruited to the damage sites, but the amount does not increase [@B029].Besides PARP-1, PARG, the enzyme that regulates PAR degradation, also plays an important role in PAR metabolism. To characterize PARG, we examined the expression of PARG following H~2~O~2~ treatment. Under physiological conditions, the expression level of PARG was relatively low, and there was no significant difference in PARG expression in the MOVAS, MEFs, MECs and MSCs. However, upon treatment with H~2~O~2~, we found that the expression of PARG increased in varying degrees in different cells, and oxidative stress induced higher expression of PARG in MOVAS ([Fig. 3](#F003){ref-type="fig"}B). Thus, it is likely that the high level of PARG expression in MOVAS is responsible for the low level of PAR in response to DNA damage.

![High expression of PARG level promotes PAR degradation in MOVAS. (A) Representative immunostaining images of PARP-1 (green) and PAR (red) in H~2~O~2~ treated MOVAS and MEFs cells at 20 min. Nuclei were stained with Hoechst 33258 (blue), and outlined by white dashed lines in enlarged boxes to denote the localization of PARP-1 and PAR in nuclei. (B) The expression of PARP-1 and PARG in cells were examined at 1 h following H~2~O~2~ treatment, β-actin was used as the protein loading control. The error bars represent the standard deviation.](BMB-48-354-g003){#F003}

PARG inhibitor rescues MOVAS from oxidative stress-induced cell death
---------------------------------------------------------------------

To further examine the role of PARG, we treated the cells with the PARG inhibitor GLTN. In the presence of the PARG inhibitor, the amount of PAR increased significantly in MOVAS following H~2~O~2~ treatment ([Fig. 4](#F004){ref-type="fig"}A). Thus, we could use PARG inhibitors to suppress PARG-dependent PAR degradation in MOVAS. Next, we wondered whether the PAR-dependent DNA damage repair is enhanced in the presence of the PARG inhibitor. As seen in [Fig. 4](#F004){ref-type="fig"}B, C, the PARG inhibitor significantly reduced oxidative stress-induced DNA damage in MOVAS as the number of short DNA fragments was significantly reduced during the 30 min recovery following H~2~O~2~ treatment (Control group: 11.03 ± 1.98, inhibitor group: 5.11 ± 1.91, P = 0.000). Moreover, the number of oxidative stress-induced DSBs were lower with the PARG inhibitor treatment as the number of γH2AX foci was remarkably reduced (Control group: 38.20 ± 2.77, inhibitor group: 16.20 ± 5.16, P = 0.000) ([Fig. 4](#F004){ref-type="fig"}D, E). In addition, accumulative evidence has proven that oxidative stress induces cell death [@B030], which appears to be a major molecular pathogenesis of atherosclerosis [@B031]. Thus, we wondered whether inhibition of PARG could suppress MOVAS death from oxidative stress. As shown in [Fig. 4](#F004){ref-type="fig"}F, when MOVAS were incubated with H~2~O~2~ for 8 hours, 55.4 ± 2.2% of the cells underwent death as detected by the MTT assay. However, when the cells were pretreated with 0.5, 5, and 25 ㎛ PARG inhibitor (GLTN) for 1 hour, the percentage of cell death decreased to 52.2 ± 3.0% (P = 0.380), 41.6 ± 5.9% (P = 0.041), and 34.0 ± 7.1% (P = 0.000) respectively, suggesting that the inhibition of PARG effectively rescues the cells from oxidative stress-induced death.

![PARG inhibitor reduced oxidative DNA damage level and cell death. (A) Following PARG treatment, PAR synthesis in MOVAS was examined by dot blot. (B, C) MOVAS were pre-treated with or without PARG inhibitor followed by H~2~O~2~. DNA breaks were examined at 20 min following H~2~O~2~ treatment by alkaline comet assays. Tail moment was measured. (D, E) MOVAS were pre-treated with or without PARG inhibitor. H~2~O~2~-induced DSBs were examined and the foci of *γ*H2AX in each cell were counted (n = 15). (F) MOVAS were pre-treated with or without PARG inhibitor and then exposed to 100 ㎛ H~2~O~2~. Cell viability was evaluated using an MTT assay. The error bars represent the standard deviation, \*P ＜ 0.05.](BMB-48-354-g004){#F004}

Normally PARPs and PARG maintain the balance of PARylation. However, during pathological events such as excessive and unrepairable oxidant DNA damage, highly activated PARPs synthesize large amounts of PAR in a few seconds. The PAR synthesis also triggers rapid PAR degradation with the over-activated PARG within a few minutes following DNA damage. This vicious cycle not only impairs DNA damage repair but also leads to intracellular ATP depletion and NAD [@B032], [@B033]. Our results show that VSMCs death may result from excessive PARG expression to impair PAR-dependence DNA damage repair. In recent years, PARP-1 inhibitors have shown promising therapeutic effects on atherosclerosis, and this effect is mainly associated with the maintenance of cellular NAD and ATP level [@B033], [@B034]. Similarly, suppression of PARG was likely to protect cells from oxidative DNA damage and facilitated cell survival in our results. In addition, PARG inhibitor protection is supported in the ischemic animal model [@B035] and in cells [@B036]. Here, we demonstrate that PARG inhibitor treatment contributes to genomic stability and anti-oxidative stress injury, and positively regulates the viability of VSMCs, which reveals a potential therapeutic strategy for arteriosclerosis.

In conclusion, our study suggests that a high level of endogenous PARG in VSMCs impairs oxidative DNA damage repair, inducing the death of VSMCs during atherosclerosis. PARG inhibitor treatment suppresses PARG activity and facilitates DNA damage repair in VSMCs by prolonging PARylation. Thus, PARG acts as a mediator of cardiovascular disease, and PARylation may play a pivotal protective role as an antioxidant defense mechanism by maintaining VSMCs function under pathologic conditions of oxidative stress. Hence, PARG inhibitors may provide a novel clinical treatment for suppressing arteriosclerosis caused by oxidative damage.

MATERIALS AND METHODS
=====================

Materials and Methods are described in the online data supplement, available at <http://www.bmbreports.org/>.
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